News

Kidney International® 

The Mayo MGRS Prediction Tool calculates the risk of finding monoclonal gammopathy of renal significance in a kidney biopsy in patients with monoclonal gammopathy  

Determining which patients with chronic kidney disease (CKD) and monoclonal gammopathy should undergo a kidney biopsy to diagnose monoclonal gammopathy of renal significance (MGRS) remains a clinical challenge. 

Researchers developed and validated the Mayo MGRS Prediction Tool, using eight clinical variables from blood and urine tests to assess the risk of MGRS lesions in a cohort of 280 patients. 

The tool demonstrated strong predictive performance and can help clinicians better identify patients with CKD at risk of MGRS, guiding biopsy decisions. 

Kidney International Reports® 

Point-of-care testing and integrated digital health technology for chronic kidney disease screening in high-risk populations of India 

CKD often goes undiagnosed in its early stages, especially in high-risk and underserved populations, leading to progression and costly treatments. 

This pilot study tested the feasibility of using point-of-care testing (POCT) and digital health tools to screen for CKD in over 2,000 individuals from high-risk urban and rural communities in Andhra Pradesh, India. 

CKD was identified in more than half of participants, yet only a small percentage were aware of their condition, highlighting the potential of POCT and digital health tools to enable early detection and reduce care costs.